Connection

Thomas Nathaniel to Tissue Plasminogen Activator

Back to Details
This is a "connection" page, showing publications Thomas Nathaniel has written about Tissue Plasminogen Activator.
Thomas Nathaniel
Connection Strength
7.230
Tissue Plasminogen Activator
  1. Clinical Risk Factors Associated with Ambulatory Outcome in Acute Ischemic Stroke Patient Smokers Treated with Thrombolytic Therapy. Am J Med Sci. 2021 10; 362(4):363-374.
    View in: PubMed
    Score: 0.626
  2. Thrombolytic therapy in ischemic stroke patients with pre-stroke depression in the telestroke vs non-telestroke. J Stroke Cerebrovasc Dis. 2020 Sep; 29(9):104890.
    View in: PubMed
    Score: 0.586
  3. Ischemic stroke with a preceding Trans ischemic attack (TIA) less than 24 hours and thrombolytic therapy. BMC Neurol. 2020 May 19; 20(1):197.
    View in: PubMed
    Score: 0.583
  4. Cholesterol reducer and thrombolytic therapy in acute ischemic stroke patients. Lipids Health Dis. 2020 May 06; 19(1):84.
    View in: PubMed
    Score: 0.581
  5. Gender and thrombolysis therapy in acute ischemic stroke patients with incidence of obesity. Neurol Sci. 2019 Sep; 40(9):1829-1839.
    View in: PubMed
    Score: 0.542
  6. Gender and thrombolysis therapy in stroke patients with incidence of dyslipidemia. BMC Womens Health. 2019 01 16; 19(1):11.
    View in: PubMed
    Score: 0.531
  7. Thrombolysis Therapy in Specialized and Non-specialized Stroke Units. Arch Med Res. 2018 11; 49(8):588-597.
    View in: PubMed
    Score: 0.531
  8. Predictors of thrombolysis in the telestroke and non telestroke settings for hypertensive acute ischemic stroke patients. BMC Neurol. 2018 Dec 21; 18(1):215.
    View in: PubMed
    Score: 0.529
  9. In a stroke cohort with incident hypertension; are more women than men likely to be excluded from recombinant tissue-type Plasminogen Activator (rtPA)? J Neurol Sci. 2018 04 15; 387:139-146.
    View in: PubMed
    Score: 0.498
  10. Gender Differences in Exclusion Criteria for Recombinant Tissue-Type Plasminogen Activator. J Stroke Cerebrovasc Dis. 2016 Nov; 25(11):2569-2574.
    View in: PubMed
    Score: 0.451
  11. Co-morbid conditions in use of recombinant tissue plasminogen activator (rt-PA) for the treatment of acute ischaemic stroke. Brain Inj. 2016; 30(10):1261-5.
    View in: PubMed
    Score: 0.448
  12. Tissue plasminogen activator (rt-PA) in acute ischemic stroke: Outcomes associated with ambulation. Restor Neurol Neurosci. 2015; 33(3):301-8.
    View in: PubMed
    Score: 0.401
  13. Stroke Severity among Men and Women Acute Ischemic Stroke Patients in the Telestroke Network. Cerebrovasc Dis Extra. 2022; 12(2):93-101.
    View in: PubMed
    Score: 0.168
  14. Retrospective analysis of comorbidities in stroke patients with a history of obstructive sleep apnea treated with thrombolytic therapy. J Vasc Nurs. 2022 06; 40(2):74-85.
    View in: PubMed
    Score: 0.164
  15. Acute Ischemic Stroke and Heart Failure: Stroke Risk Factors Associated with Exclusion from Thrombolytic Therapy. Clin Appl Thromb Hemost. 2022 Jan-Dec; 28:10760296221116347.
    View in: PubMed
    Score: 0.163
  16. Risk factors and ambulatory outcome in ischemic stroke patients with pre-stroke depression. J Vasc Nurs. 2021 Dec; 39(4):91-99.
    View in: PubMed
    Score: 0.159
  17. In acute ischemic stroke patients with smoking incidence, are more women than men more likely to be included or excluded from thrombolysis therapy? Womens Health (Lond). 2020 Jan-Dec; 16:1745506520922760.
    View in: PubMed
    Score: 0.142
  18. Clinical Risk Factors in Thrombolysis therapy: Telestroke Versus Nontelestroke. J Stroke Cerebrovasc Dis. 2018 Sep; 27(9):2524-2533.
    View in: PubMed
    Score: 0.127
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.